NCT01122329已完成4 期
A Single-site Positron Emission Tomography (PET) Study of the Cerebral Metabolic Effects of AC-1202 (Axona®) Treatment in Mild-to-Moderate Alzheimer's Disease (AD)
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Regional cerebral blood flow (rCBF)
研究概览
简要总结
This study will examine the brain metabolic effects of AC-1202 (Axona®), a medical food for Alzheimer's disease. Subjects who meet entry criteria will undergo H215O positron emission tomography prior to and 90 minutes after consumption of Axona® at baseline and then again after 45 days of treatment. Cognitive testing will also be conducted at baseline and day 45.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of probable AD (NINDS-ADRDA criteria(32))
- •Age 50 - 90 (inclusive)
- •MMSE range: 10 to 28
- •Participants may be taking medications for AD, provided that the dose of these medications has been stable for > 90 days
- •Proficiency in English to be able to perform cognitive tests
- •A caregiver must be available to monitor and administer treatment and to accompany the subject to every clinical visit.
排除标准
- •Inability for any reason to undergo PET/CT scans
- •Previous treatment with AC-1202
- •Allergic to milk or soy
- •Presence of neurodegenerative disease other than AD
- •History of stroke or other injury that could result in cognitive impairment
- •Psychiatric disorder
- •Diabetes mellitus
- •Recent (<90 days) changes to medications prescribed for cognitive reasons or with the potential to impact cognition
- •Irritable bowel syndrome (IBS) or other gastrointestinal conditions that could interfere with treatment compliance
- •Any factor deemed by the investigator to be likely to interfere with study conduction
研究组 & 干预措施
inactive food packet
Placebo Comparator
干预措施: Placebo (Dietary Supplement)
Axona®
Active Comparator
干预措施: caprylidene (Dietary Supplement)
结局指标
主要结局
Regional cerebral blood flow (rCBF)
时间窗: 45 days after initation of treatment with Axona®
Regional cerebral blood flow (rCBF)
时间窗: At baseline
Regional cerebral blood flow (rCBF)
时间窗: 90 minutes after initation of treatment with Axona®
次要结局
- Examine differences between ApoE ε4 carriers and noncarriers in changes on rCBF and cognition(45 days after initiation of treatment with Axona®)
- To examine the effect of AC-1202 on cognition(45 days after initiation of treatment with Axona®)
- Examine differences between ApoE ε4 carriers and noncarriers in changes on rCBF and cognition(At baseline)
- To examine the effect of AC-1202 on cognition(At baseline)
- Examine differences between ApoE ε4 carriers and noncarriers in changes on rCBF and cognition(At 90 minutes after initiation of treatment with Axona®)
- To examine the effect of AC-1202 on cognition(At 90 minutes after initiation of treatment with Axona®)
研究者
Joshua Grill, PhD
Assistant Professor
University of California, Los Angeles
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1Alzheimer DiseaseNCT06129838Washington University School of Medicine80
已完成
1 期
Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan StudyCognitive DisordersNCT00937846GlaxoSmithKline4
已完成
不适用
Amyloid positron emission tomography (PET) imaging in the timely diagnosis of Alzheimer's diseaseMental and Behavioural DisordersDementia in Alzheimer diseaseAlzheimer's diseaseISRCTN17685148Sussex Partnership NHS Foundation Trust10
暂停
1 期
Positron Emission Tomography of Amyloid in Alzheimer's DiseaseAlzheimer's DiseaseNCT00205621Amsterdam UMC, location VUmc50
已完成
不适用
Brain Imaging in Alzheimer's DiseaseAlzheimer DiseaseNCT00039702National Institute of Mental Health (NIMH)40